Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Drugs

• Publication date

  2016-04-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40265-016-0566-3PMID 27091215
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Current and future contraceptive options for women living with HIV

  2018cited by this paper
• Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson’s disease

  2016cited by this paper
• Improvement of dyskinesias with l‐dopa infusion in advanced Parkinson's disease

  2016cited by this paper
• Movement disorders induced by deep brain stimulation.

  2016cited by this paper
• A Placebo‐Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa‐Induced Dyskinesia

  2016cited by this paper
• Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.

  2015cited by this paper
• Putaminal serotonergic innervation

  2015cited by this paper
• Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease

  2015cited by this paper
• Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.

  2015cited by this paper
• Medication-Induced Movement Disorders: L-Dopa dyskinesias

  2015cited by this paper
• The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson’s disease

  2015cited by this paper
• Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics

  2015cited by this paper
• Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study

  2015cited by this paper
• Effect of Subthalamic Deep Brain Stimulation on Levodopa-Induced Dyskinesia in Parkinson's Disease

  2015cited by this paper
• Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans

  2015cited by this paper
• Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson’s Disease

  2015cited by this paper
• Dual κ‐agonist/μ‐antagonist opioid receptor modulation reduces levodopa‐induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease

  2015cited by this paper
• The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience

  2015cited by this paper
• Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions

  2015cited by this paper
• Serotonin/dopamine transporter ratio as a predictor of l-dopa–induced dyskinesia

  2015cited by this paper
• Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders.

  2015cited by this paper
• Novel formulations and modes of delivery of levodopa

  2015cited by this paper
• Respiratory dyskinesia in a patient with Parkinson disease successfully treated with STN DBS

  2015cited by this paper
• Advances in functional neurosurgery for Parkinson's disease

  2015cited by this paper
• A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study

  2015cited by this paper
• Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the Striatum

  2015cited by this paper
• Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.

  2015cited by this paper
• The medical treatment of Parkinson disease from James Parkinson to George Cotzias

  2015cited by this paper
• Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)

  2015cited by this paper
• Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.

  2015cited by this paper
• Zonisamide improves wearing‐off in Parkinson's disease: A randomized, double‐blind study

  2015cited by this paper
• Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches.

  2015cited by this paper
• New treatments for levodopa‐induced motor complications

  2015influential reference
• Current treatment and future prospects of dopa-induced dyskinesias.

  2015influential reference
• Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson’s disease: a meta-analysis

  2015cited by this paper
• Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned.

  2015cited by this paper
• The therapeutic potential of cannabinoids for movement disorders

  2015cited by this paper
• Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease

  2015cited by this paper
• Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.

  2014cited by this paper
• Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.

  2014cited by this paper
• Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease.

  2014cited by this paper
• Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

  2014cited by this paper
• Parkinson disease subtypes.

  2014cited by this paper
• Comparing clinical features of young onset, middle onset and late onset Parkinson's disease.

  2014cited by this paper
• Surgical Options for Levodopa-Induced Dyskinesia in Parkinson’s Disease

  2014cited by this paper
• Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.

  2014cited by this paper
• Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial

  2014cited by this paper
• Adenosine receptors and dyskinesia in pathophysiology.

  2014cited by this paper
• Low-frequency repetitive transcranial magnetic stimulation for dyskinesia and motor performance in Parkinson's disease.

  2014cited by this paper
• Withdrawing amantadine in dyskinetic patients with Parkinson disease

  2014cited by this paper
• An Eight-Year Clinic Experience with Clozapine Use in a Parkinson’s Disease Clinic Setting

  2014cited by this paper
• Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders

  2014cited by this paper
• New treatments for the motor symptoms of Parkinson’s disease

  2014cited by this paper
• Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.

  2014cited by this paper
• Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease

  2014cited by this paper
• Cortical effects of deep brain stimulation: implications for pathogenesis and treatment of Parkinson disease.

  2014cited by this paper
• Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.

  2014cited by this paper
• Two‐year, randomized, controlled study of safinamide as add‐on to levodopa in mid to late Parkinson's disease

  2014cited by this paper
• Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.

  2013cited by this paper
• The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease

  2013cited by this paper
• Ropinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease

  2013cited by this paper
• Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease.

  2013cited by this paper
• Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.

  2013cited by this paper
• Study of the antidyskinetic effect of eltoprazine in animal models of levodopa‐induced dyskinesia

  2013cited by this paper
• Which dyskinesia scale best detects treatment response?

  2013cited by this paper
• Caffeine consumption and risk of dyskinesia in CALM‐PD

  2013cited by this paper
• Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease

  2013cited by this paper
• Deep brain stimulation for Parkinson's disease - patient selection.

  2013cited by this paper
• Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments

  2013cited by this paper
• Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study

  2013cited by this paper
• Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.

  2013cited by this paper
• Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease

  2012cited by this paper
• GPi and STN deep brain stimulation can suppress dyskinesia in Parkinson's disease.

  2012cited by this paper
• Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease

  2012cited by this paper
• Patient Diaries As a Clinical Endpoint in Parkinson's Disease Clinical Trials

  2012cited by this paper
• Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)

  2012cited by this paper
• New insights into the mechanism of drug-induced dyskinesia

  2012cited by this paper
• Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.

  2012cited by this paper
• Anti‐dyskinetic mechanisms of amantadine and dextromethorphan in the 6‐OHDA rat model of Parkinson’s disease: role of NMDA vs. 5‐HT1A receptors

  2012cited by this paper
• Abstracts of the Sixteenth International Congress of Parkinson's Disease and Movement Disorders. June 17-21, 2012. Dublin, Ireland.

  2012cited by this paper
• Therapies in Parkinson's disease.

  2012cited by this paper
• Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations

  2011cited by this paper
• Therapies for dopaminergic‐induced dyskinesias in parkinson disease

  2011cited by this paper
• The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

  2011influential reference
• The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease

  2011cited by this paper
• Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials

  2011cited by this paper
• Unilateral GPi-DBS as a Treatment for Levodopa-Induced Respiratory Dyskinesia in Parkinson Disease

  2011cited by this paper
• Differential genetic susceptibility in diphasic and peak‐dose dyskinesias in Parkinson's disease

  2011cited by this paper
• Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders

  2011cited by this paper
• Levetiracetam for the management of levodopa‐induced dyskinesias in Parkinson's disease

  2011cited by this paper
• Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.

  2011cited by this paper
• The motor phenotype of Parkinson's disease in relation to age at onset

  2011cited by this paper
• l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment.

  2011cited by this paper
• Calcium‐permeable AMPA receptors are involved in the induction and expression of l‐DOPA‐induced dyskinesia in Parkinson’s disease

  2010cited by this paper
• Classifying risk factors for dyskinesia in Parkinson's disease.

  2010cited by this paper
• Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease

  2010cited by this paper
• Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease.

  2010cited by this paper
• Camptocormia, head drop and other bent spine syndromes: Heterogeneous etiology and pathogenesis of Parkinsonian deformities

  2010cited by this paper
• Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease

  2010cited by this paper
• Repetitive transcranial magnetic stimulation for levodopa‐induced dyskinesias in Parkinson's disease

  2009cited by this paper

• The role of neuroactive steroids in psychiatric and neurological disorders: Neurobiology and therapeutic perspectives.

  2025cites this paper
• Developmental Dopamine Loss Rewires Striatal Circuits to Promote Locomotion

  2025cites this paper
• Parkinson Disease.

  2025cites this paper
• Advances in the Pharmacological Management of Parkinson’s Disease

  2025cites this paper
• Levodopa-carbidopa related severe mixed dyskinesia in a patient with advanced Parkinson’s disease admitted to the intensive care unit

  2025cites this paper
• Acupuncture versus sham acupuncture in the treatment of insomnia for patients with Parkinson’s disease: a randomized controlled clinical trial

  2025cites this paper
• Beyond dopamine: exploring endocannabinoids in Parkinson’s disease

  2024cites this paper
• The Potential of Metabolomics to Find Proper Biomarkers for Addressing the Neuroprotective Efficacy of Drugs Aimed at Delaying Parkinson’s and Alzheimer’s Disease Progression

  2024cites this paper
• The impact of bilateral subthalamic nucleus deep brain stimulation on dyskinesia and levodopa equivalent daily dose in advanced Parkinson’s disease

  2024cites this paper
• Low-Frequency Quadruple Target Transcranial Magnetic Stimulation for Severe Levodopa-Induced Dyskinesia in Parkinson's Disease. A single case report

  2024cites this paper
• Parkinson disease therapy: current strategies and future research priorities

  2024cites this paper
• Exploring the Role of Deutetrabenazine in the Treatment of Chorea Linked with Huntington's Disease.

  2024cites this paper
• Exploring Magnetic and Electrical Brain Stimulation in Parkinsonian Dyskinetic Monkeys

  2024cites this paper
• Neuroactive steroids and Parkinson's disease: a review of human and animal studies.

  2023cites this paper
• Unravelling the Parkinson’s puzzle, from medications and surgery to stem cells and genes: a comprehensive review of current and future management strategies

  2023cites this paper
• Activation of mGlu2/3 receptors in the striatum alleviates L-DOPA-induced dyskinesia and inhibits abnormal postsynaptic molecular expression.

  2023cites this paper
• CRISPR/sgRNA-directed synergistic activation mediator (SAM) as a therapeutic tool for Parkinson´s disease

  2023cites this paper
• Levodopa-Induced Dyskinesias in Parkinson’s Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions

  2023cites this paper
• The Management of Parkinson’s Disease: An Overview of the Current Advancements in Drug Delivery Systems

  2023cites this paper
• Impact of Sex on Neuroimmune contributions to Parkinson's disease.

  2023cites this paper
• Current and Possible Future Therapeutic Options for Huntington’s Disease

  2022cites this paper
• Levodopa-induced dyskinesia: a historical review of Parkinson’s disease, dopamine, and modern advancements in research and treatment

  2022cites this paper
• Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence

  2022cites this paper
• Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies

  2022cites this paper
• [Clinical phenomenology and pathophysiology of daytime and nighttime imperative movements].

  2022cites this paper
• Therapeutic Approaches to Non-Motor Symptoms of Parkinson's Disease: A Current Update on Preclinical Evidence

  2022cites this paper
• Amantadine extended release capsules (GOCOVRI®) in Parkinson’s disease: a profile of its use in the USA

  2022cites this paper
• Dancing Feet Dyskinesia in a Patient with GBA-PD

  2021cites this paper
• Amantadine treatment and delayed onset of levodopa‐induced dyskinesia in patients with early Parkinson's disease

  2021cites this paper
• Novel Pharmacotherapies for L-DOPA-Induced Dyskinesia

  2021cites this paper
• ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.

  2021cites this paper
• Diverse midbrain dopaminergic neuron subtypes and implications for complex clinical symptoms of Parkinson’s disease

  2021cites this paper
• Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia

  2021cites this paper
• Levodopa partially rescues microglial numerical, morphological, and phagolysosomal alterations in a monkey model of Parkinson's disease.

  2020cites this paper
• Extracellular Vesicles as Nanotherapeutics for Parkinson’s Disease

  2020cites this paper
• Parkinsonian Drugs: Indications

  2020cites this paper
• Botulinum Toxin Treatment in Surgery, Dentistry, and Veterinary Medicine

  2020cites this paper
• Levodopa Inhalation Powder: A Review in Parkinson’s Disease

  2020cites this paper
• Treatment of Tardive Dyskinesia.

  2020cites this paper
• Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease

  2020cites this paper
• Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease

  2020cites this paper
• PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial

  2020cites this paper
• Dopamine agonists in treatment of Parkinson's disease: an overview

  2020cites this paper
• Levodopa partially rescues microglial numerical, morphological, and phagolysosomal alterations in a monkey model of Parkinson’s disease Running title: Levodopa partially rescues microglia

  2020cites this paper
• Stereotypies in adults: a systematic review.

  2020cites this paper
• Evidence-Based Review of Current Botulinum Toxin Treatment Indications in Medicine

  2020cites this paper
• Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats.

  2020cites this paper
• Cerebellar continuous theta burst stimulation reduces Levodopa-induced dyskinesias and decreases serum BDNF levels.

  2019cites this paper
• Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease

  2019cites this paper
• ALDH1A1 regulates postsynaptic μ–opioid receptor expression in dorsal striatal projection neurons and mitigates dyskinesia through transsynaptic retinoic acid signaling

  2019cites this paper
• Dyskinesia and FAB score predict future falling in Parkinson's disease

  2019cites this paper
• Extended-Release Amantadine for Levodopa-Induced Dyskinesia

  2019cites this paper
• Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease

  2019cites this paper
• Comparison of selegiline and levodopa combination therapy versus levodopa monotherapy in the treatment of Parkinson’s disease: a meta-analysis

  2019cites this paper
• Young-onset Parkinson's disease: Its unique features and their impact on quality of life.

  2019cites this paper
• Repetitive Transcranial Magnetic Stimulation in Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease

  2019cites this paper
• A Stage-Based Approach to Therapy in Parkinson’s Disease

  2019influential citation
• The Parkinson's Disease Activities of Daily Living, Interference, and Dependence Instrument

  2019cites this paper
• The increased gray matter volumes of precentral gyri in Parkinson's disease patients with diphasic dyskinesia

  2019cites this paper
• Parkinson's disease: Diagnosis and appreciation of comorbidities.

  2019cites this paper
• Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.

  2019cites this paper
• Accidental Modopar© Poisoning in a Two-Year-Old Child: A Case Report

  2019cites this paper
• Pallidal versus subthalamic nucleus deep brain stimulation for levodopa‐induced dyskinesia

  2019cites this paper
• The Possible Role of Anti-Epileptic Drugs (AEDS) in Treating Levodopa Induced Dyskinesia (LID)

  2019cites this paper
• Antipsychotic-Induced Neurological Adverse Events

  2019cites this paper
• [Movement disorders: An update].

  2018cites this paper
• Molecular basis of dopamine replacement therapy and its side effects in Parkinson’s disease

  2018cites this paper
• Botulinum Toxin Treatment in Parkinson’s Disease and Atypical Parkinsonian Disorders

  2018cites this paper
• Evaluation of nitrocatechol bearing cyclic chalcones and related analogues as dual monoamine oxidase and catechol-O-methyltransferase inhibitors

  2018cites this paper
• Treatment options for chorea

  2018influential citation
• Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs

  2018cites this paper
• Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following l-DOPA Administration in Hemi-Parkinsonian Rats

  2018cites this paper
• Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinson’s disease patients

  2018cites this paper
• An mGlu4‐Positive Allosteric Modulator Alleviates Parkinsonism in Primates

  2018cites this paper
• Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features

  2018cites this paper
• Amantadine Extended-Release (GOCOVRI™): A Review in Levodopa-Induced Dyskinesia in Parkinson’s Disease

  2018cites this paper
• Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease

  2018influential citation
• Acupuncture Alleviates Levodopa-Induced Dyskinesia via Melanin-Concentrating Hormone in Pitx3-Deficient aphakia and 6-Hydroxydopamine-Lesioned Mice

  2018cites this paper
• Neuropsychiatric symptoms and brain dopamine transporter imaging in Parkinson's disease

  2018cites this paper
• The nosology of tardive syndromes.

  2018cites this paper
• Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors

  2018cites this paper
• Motor Complications of Dopaminergic Medications in Parkinson's Disease

  2017cites this paper
• 4R-Cembranoid Improves Outcomes after 6-Hydroxydopamine Challenge in Both In vitro and In vivo Models of Parkinson's Disease

  2017cites this paper
• Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study

  2017cites this paper
• Scopolamine alleviates involuntary lingual movements: tardive dyskinesia or dystonia?

  2017cites this paper
• Diagnosis and Management of Parkinson's Disease

  2017cites this paper
• Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias

  2017cites this paper
• Extended-Release Amantadine-A Smart Pill for Treatment of Levodopa-Induced Dyskinesia but Does the Evidence Justify the Cost?

  2017cites this paper
• [Pharmacological treatment of motor symptoms in Parkinson's diseases].

  2017cites this paper
• Chapter 11 - Drugs That Affect Autonomic Functions or the Extrapyramidal System

  2017cites this paper
• Treatment strategies in advanced Parkinson's disease: Review of the literature

  2017cites this paper
• Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy

  2017cites this paper
• Extended-Release Amantadine-A Smart Pill for Treatment of Levodopa-Induced Dyskinesia but Does the Evidence Justify the Cost?

  2017cites this paper
• Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.

  2017cites this paper
• scopolamine alleviates involuntary lingual movements: tardive dyskinesia or dystonia?

  2017cites this paper
• Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease

  2017influential citation
• Media hype: Patient and scientific perspectives on misleading medical news

  2017cites this paper
• Factors associated with motor complications in Parkinson's disease

  2017cites this paper
• Medikamentöse Therapie der motorischen Symptome beim Morbus Parkinson

  2017cites this paper
• Opioid system in L-DOPA-induced dyskinesia

  2017cites this paper